The four-month extended study enrolled 42 growth hormone deficient adults (34 men and eight women) who had received a daily growth hormone therapy and who had previously participated in the Phase II trial that tested a once-weekly hGH-CTP regimen or in the pilot assessment of a twice-monthly hGH-CTP regimen.
Preliminary analysis of the extended study's data also confirmed the safety and tolerability of hGH-CTP, with no unexpected adverse events. In addition, there was no indication that high doses of hGH-CTP can induce excessive levels of insulin-like growth factor 1 (IGF-1) above the normal range. The study found that the proportion of patients receiving once-weekly injections of hGH-CTP who achieved the normal range of IGF-1 levels was comparable with the proportion of patients who received daily dosages of commercial growth hormones.
Prolor's share price rose 1.5% by mid-afternoon on the TASE following the announcement to NIS 20.13, after falling 1.9% yesterday on Nasdaq to $5.24, giving a market cap of $290 million.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments